Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-cell receptors (BCRs) specific for Hevea brasiliensis latex allergens are specialized membrane-bound immunoglobulins on the surface of B lymphocytes that recognize and bind to specific protein components of natural rubber latex, such as Hev b 1 (elongation factor), Hev b 3 (small rubber particle protein), and Hev b 6.02 (hevein) (Source: WHO/IUIS Allergen Nomenclature). These receptors are central to the pathogenesis of latex allergy, a Type I hypersensitivity reaction that is particularly prevalent among healthcare workers and individuals who have undergone multiple surgical procedures (Source: PMID: 21651601). Upon binding to latex allergens, these BCRs trigger B-cell activation and differentiation into plasma cells that secrete allergen-specific IgE antibodies, which then sensitize mast cells and basophils. Subsequent exposure to latex leads to the cross-linking of these IgE antibodies, causing the release of inflammatory mediators that result in clinical symptoms ranging from contact urticaria and asthma to life-threatening anaphylaxis (Source: PMID: 28939245). In a therapeutic context, these BCRs are the primary targets of allergen-specific immunotherapy (ASIT), which aims to reprogram the immune system toward tolerance and the production of protective IgG4 antibodies (Source: PMID: 29103400). Monitoring the frequency and specificity of these BCRs, as well as the levels of the antibodies they produce, is essential for the diagnosis and management of latex-sensitive patients.
Allergen-specific immunotherapy (ASIT) modulates the immune response by repeatedly exposing these B-cell receptors to controlled doses of latex allergens, which induces peripheral T-cell tolerance, promotes B-cell class switching from IgE to protective IgG4, and reduces the overall sensitivity of the immune system to the allergen (Source: PMID: 30033913, PMID: 28939245).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell receptor specific for Hevea brasiliensis latex allergens (BCR-Hev-b) (BCR-Hev-b).